Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs MiMedx Group, Inc.

SG&A Expenses: Protagonist vs. MiMedx (2014-2023)

__timestampMiMedx Group, Inc.Protagonist Therapeutics, Inc.
Wednesday, January 1, 2014904800001860000
Thursday, January 1, 20151333840002963000
Friday, January 1, 20161799970006961000
Sunday, January 1, 201722011900011779000
Monday, January 1, 201825852800013697000
Tuesday, January 1, 201919820500015749000
Wednesday, January 1, 202018102200018638000
Friday, January 1, 202119835900027196000
Saturday, January 1, 202220878900031739000
Sunday, January 1, 202321112400033491000
Loading chart...

Unleashing the power of data

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of biotechnology and medical devices, understanding financial health is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Protagonist Therapeutics, Inc. and MiMedx Group, Inc. from 2014 to 2023. Over this period, MiMedx Group consistently outspent Protagonist Therapeutics, with SG&A expenses peaking in 2018 at approximately 258 million dollars, a 185% increase from 2014. In contrast, Protagonist Therapeutics saw a more modest rise, with expenses growing nearly 18 times from 2014 to 2023, reaching around 33 million dollars. This stark difference highlights MiMedx's aggressive spending strategy compared to Protagonist's more conservative approach. Such insights are invaluable for investors and stakeholders aiming to gauge the operational strategies and financial priorities of these companies. As the industry evolves, tracking these expenses can offer a window into future growth and sustainability strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025